NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

心房纖維顫動:競爭情形 (2020年)

Atrial Fibrillation - Competitive Landscape in 2020

出版商 GlobalData 商品編碼 995612
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
心房纖維顫動:競爭情形 (2020年) Atrial Fibrillation - Competitive Landscape in 2020
出版日期: 2020年12月31日內容資訊: 英文 51 Pages
簡介

抗凝固劑和抗心律不整劑是醫藥品開發企業的主要關心領域。在開發平台有32種藥物,其中92種是離子通道阻斷劑。在心房纖維顫動上支配著研究開發,Bayer領先。心房纖維顫動市場,由於盛行率增加預計成長,不過,由於比品牌藥促進學名藥的使用,高價的藥物的使用受到限制,妨礙市場成長。

本報告提供心房纖維顫動治療關於現在及未來的競爭情形資料,疾病概要,成藥,開發平台,臨床試驗,及評估等資訊彙整。

目錄

第1章 目錄

  • 序文
  • 簡稱
  • 相關報告
  • 今後的相關報告

第2章 摘要整理

  • 主要調查結果
  • 重要的活動

第3章 簡介

  • 調查範圍
  • 疾病概要、流行病學概要
  • 流行病學

第4章 成藥的評估

  • 成藥概要
  • 成藥的簡介

第5章 開發平台評估

  • 開發平台概要
  • 開發平台的明細:各地區
  • 開發平台的明細:各分子類型及標的
  • 藥物的優先審查指定
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 臨床試驗概要:各階段
  • 各地區的概要
  • 治療領域的展望
  • 主要贊助商
  • 登記分析
  • 實行可能性分析

第7章 商業性評估

  • 今後的市場促進因素

第8章 與社群媒體數位行銷

  • 主要的Twitter Chatter
  • 頂級品牌的網站
  • 信任來源和引用來源

第9章 附錄

  • 調查手法
  • 關於作者
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC032CL

GlobalData's "Atrial Fibrillation - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Anticoagulants and antiarrhythmic drugs are major focus of drug developers. There are 32 drugs in the pipeline, nine of which are ion channel blockers. Big pharma dominates R&D in this indication, with Bayer leading the way. Increasing prevalence expected to drive growth in atrial fibrillation market, but the promotion of generic drugs over branded options will limit the uptake of more expensive agents limiting the market growth.

This reports provides a data-driven overview of the current and future competitive landscape in atrial fibrillation therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atrial fibrillation market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1.Table of Contents

  • 1.1 Preface
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer